原發性膽汁性膽管炎治療市場：依治療類型、通路、地區分類

Primary Biliary Cholangitis Treatment Market, By Treatment Type (Ursodeoxycholic Acid, Obeticholic Acid, and Others), By Distribution Channel, By Region

出版日期: 2023年12月18日 | 出版商:

Coherent Market Insights | 英文 128 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球原發性膽汁性膽管炎治療市場預計在預測期（2023-2030年）將顯著成長。預計將從 2023 年的 6.5 億美元增至 2030 年的 11.741 億美元，複合年成長率為 8.8%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	6.5億美元
實際資料	2018-2021	預測期	2023-2030
預測期複合年成長率	8.80%	2030年市場規模預測	11.741 億美元

圖 1. 2023 年原發性膽汁性膽管炎治療的全球市場佔有率(%)（依地區）

原發性膽汁性膽管炎（PBC）是一種影響肝臟小膽管的慢性自體自體免疫肝病。隨著疾病的進展，這些膽管（稱為膽管）會結疤或受損，阻止膽汁在肝臟內自由流動，並隨著時間的推移損害肝臟。 PBC的主要症狀包括疲倦、搔癢和黃疸。如果不及時治療，PBC 最終會導致肝硬化和肝功能衰竭。原發性膽汁性膽管炎治療市場由針對該疾病發病機制和進展的各種途徑的藥物組成。熊去氧膽酸（UDCA）仍然是首選藥物，但許多患者對其反應不佳或不不耐症。奧貝膽酸和纖維酸衍生物等二線治療藥物正在出現，以解決未滿足的需求。

市場動態：

原發性膽汁性膽管炎治療市場主要是由全球 PBC 盛行率上升所推動的。根據各種估計，全球 PBC 盛行率為每百萬人 40 至 400 例。與傳統治療方法相比，具有更高療效和更好耐受性的新型二線治療方法的推出也推動了市場的發展。然而，新興市場新藥成本高、PBC 認知度低可能會抑制市場成長。具有新穎作用機制的管道藥物的出現為該市場的參與者提供了機會。監管機構核准有效且安全的治療方法將有助於滿足難治性患者的需求。

本研究的主要特點

本報告對全球原發性膽汁性膽管炎治療市場進行了詳細分析，並列出了以2022年為基準年的預測期（2023-2030）的市場規模和復合年成長率。
本報告還強調了各個區隔市場的潛在收益成長機會，並為該市場說明了一系列有吸引力的投資提案。
本報告還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。
根據以下參數對全球原發性膽汁性膽管炎治療市場的主要企業進行了分析，例如公司亮點、產品系列、主要亮點、績效和策略。
本研究涵蓋的主要公司有：Intercept Pharmaceuticals, Inc.、Highlight Therapeutics, SL、GSK plc.、百時美施貴寶公司、Enanta Pharmaceuticals、NW Biotherapeutics、Merck &Co Inc.、Ipsen Pharma、Johnson &Johnson、GENFIT、 Ironwood Pharmaceuticals , Inc.、Novartis AG、COUR Pharmaceuticals 和Kaken Pharmaceutical Co., Ltd.
該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
全球原發性膽汁性膽管炎治療市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球原發性膽汁性膽管炎治療市場的各種策略矩陣，將有助於相關人員做出決策。

Report Coverage	Report Details
Base Year:	2022	Market Size in 2023:	US$ 650 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	8.80%	2030 Value Projection:	US$ 1,174.1 Mn

Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease that affects the small bile ducts in the liver. As the disease progresses, it causes scarring and injury to these bile ducts, known as bile ductules, which stops bile from flowing freely within the liver and damaging it over time. Some key symptoms of PBC include fatigue, itching, and jaundice. If left untreated, PBC can eventually result in cirrhosis or liver failure. The primary biliary cholangitis treatment market consists of drugs that target various pathways involved in the pathogenesis and progression of the disease. Ursodeoxycholic acid (UDCA) remains the first-line treatment but many patients do not adequately respond or are intolerant to it. Second-line treatments such as obeticholic acid and fibric acid derivatives are emerging to address the unmet needs.

Market Dynamics:

The primary biliary cholangitis treatment market is primarily driven by the rising prevalence of PBC globally. According to various estimates, the global prevalence of PBC ranges between 40 and 400 cases per million. The market is also propelled by the launch of novel second-line treatment options with higher efficacy and better tolerability profiles than conventional therapies. However, the market growth can be restrained by the high costs of newer drugs and lack of awareness about PBC in developing regions. Emergence of pipeline drugs with novel mechanisms of action represents an opportunity for players in this market. Regulatory approval of efficient and safe therapies can help address the needs of refractory patients.

Key Features of the Study:

This report provides an in-depth analysis of the global primary biliary cholangitis treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global primary biliary cholangitis treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include Intercept Pharmaceuticals, Inc., Highlight Therapeutics, S.L., GSK plc., Bristol-Myers Squibb and Company, Enanta Pharmaceuticals, NW Biotherapeutics, Merck & Co Inc., Ipsen Pharma, Johnson & Johnson, GENFIT, Ironwood Pharmaceuticals, Inc., Novartis AG, COUR Pharmaceuticals, and Kaken Pharmaceutical Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global primary biliary cholangitis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global primary biliary cholangitis treatment market

Detailed Segmentation:

By Treatment Type:
- Ursodeoxycholic Acid (UDCA)
- Obeticholic Acid (Ocaliva)
- Others (Fibrates (Tricor), etc.)
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Intercept Pharmaceuticals, Inc.
- Highlight Therapeutics, S.L.
- GSK plc.
- Bristol-Myers Squibb and Company
- Enanta Pharmaceuticals
- NW Biotherapeutics
- Merck & Co Inc.
- Ipsen Pharma
- Johnson & Johnson
- GENFIT
- Ironwood Pharmaceuticals, Inc.
- Novartis AG
- COUR Pharmaceuticals
- Kaken Pharmaceutical Co., Ltd.

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Ursodeoxycholic Acid (UDCA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Obeticholic Acid (Ocaliva)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Others (Fibrates (Tricor), etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

6. Primary Biliary Cholangitis Treatment Market, By Distribution Channel, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

7. Primary Biliary Cholangitis Treatment Market, By Region, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
India
China
Japan
Australia
ASEAN
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
Brazil
Argentina
Mexico
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018 - 2030, (US$ Mn)
North Africa
Central Africa
South Africa

8. Competitive Landscape

Intercept Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Highlight Therapeutics, S.L.
GSK plc.
Bristol-Myers Squibb and Company
Enanta Pharmaceuticals
NW Biotherapeutics
Merck & Co Inc.
Ipsen Pharma
Johnson & Johnson
GENFIT
Ironwood Pharmaceuticals, Inc.
Novartis AG
COUR Pharmaceuticals
Kaken Pharmaceutical Co., Ltd.
Analyst Views

9. Section

Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

全球原發性硬化性膽管炎市場：依藥物類別、給藥途徑、通路及地區

原發性膽汁性膽管炎治療市場 - 按藥物（熊去氧膽酸、奧貝膽酸）、用途（人類、獸醫）、配銷通路（醫院藥房、藥房和零售藥房、在線藥房） - 全球預測（ 2024 - 2032）

原發性膽汁性膽管炎治療藥物市場：依藥物類型、通路劃分：2023-2032年全球機會分析與產業預測

FAQ

原發性膽汁性膽管炎治療市場：依治療類型、通路、地區分類